Pyramid Schemes and Pipeline Dreams: Adapting to a Tiered Regulatory System for New Drugs
By
Michael McCaughan / Email the Author / The RPM Report November 2007, Vol. 3, No. 10
Feature Articles / Word Count: 3127 / Article # 2007500189
Executive Summary
FDA's new drug safety authorities suggest that the focus of drug development and lifecycle management strategies need to change. It is no longer a question of what it takes to get approval from FDA, but rather what kind of approval you can get.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.